PU-PH, Cardiologue au CHU de Toulouse et Co-fondateur de Viaomer - France
Jacques Amar (JA) is a cardiologist and a University Professor of Therapeutic. JA raised the hypothesis of tissue microbiota, contributed to validate this hypothesis and to depict the role of tissue microbiota on cardiac and metabolic disease.In 2003, from a population-based study showing a link between the innate defence system against endotoxin and aortic stiffness, JA raised the hypothesis that the translocation of a bacterial component plays a key role on cardiovascular system (Amar et al J Hypertens. 2003). In order to explore this powerful hypothesis, after leaving the INSERM unit dedicated to epidemiological research on cardiovascular diseases, he joined the Burcelin’s INSERM team. Together they redirected the objectives of the team towards the exploration of the role of bacterial translocation on metabolic disease and associated cardiovascular complications. He co-authored (first author) in 2007 a key paper demonstrating the role of LPS translocation on metabolic disease. Then, he hypothesised that beyond LPS, bacterial translocation is also involved in cardiometabolic diseases. He published, as first author, the first paper (Amar et al Diabetologia 2011) showing in a population-based study the associations between blood bacterial DNA and the onset of diabetes and cardiovascular diseases. Furthermore, he published, a paper establishing the causative role of bacterial translocation of alive bacteria on the onset of hyperglycemia in mice (Amar et al Embo Mol Med 2011 –). He published, in 2016 (Paisse et al Tranfusion in press) in the context of the company, he founded in 2011, the first comprehensive description of blood microbiota from healthy donors.